Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Targeting the DNA Damage Response Pathway in MLL- rearranged B-Acute Lymphoblastic Leukemias

S. Haihua Chu, PhD, Evelyn Junyao Song, BS, Jonathan Chabon, BS, Janna Minehart, BS, Zhaohui Feng, BM, BS, Kenneth Ross, PhD, Richard Koche, PhD, Andrei V. Krivtsov, PhD, Scott Armstrong, MD PhD

Blood (2017) 130 (Supplement 1): 3880.

https://doi.org/10.1182/blood.V130.Suppl_1.3880.3880

Published: 2017

Journal Articles

Reciprocal Regulation of BCL6 and MLL Expression As a Vulnerability in MLL -Rearranged Acute Lymphoblastic Leukemia

Lai N Chan, Christian Hurtz, PhD, Huimin Geng, PhD, Cheryl L. Willman, MD, William L. Carroll, MD, Scott Armstrong, MD PhD, Thomas Arthur Milne, PhD BSc, MSc, Markus Muschen, MD

Blood (2017) 130 (Supplement 1): 1210.

https://doi.org/10.1182/blood.V130.Suppl_1.1210.1210

Published: 2017

Journal Articles

LSD1 Inhibition Exerts Its Anti-Leukemic Effect By Recommissioning PU.1- and C/Ebpα-Dependent Enhancers in AML

Monica Cusan, MD, Sheng Cai, MD PhD, Helai P Mohammad, PhD, Andrei V. Krivtsov, PhD, Alan Chramiec, Evangelia Loizou, Daniel G. Tenen, MD, Min Ye, PhD, Britta Will, PhD, Ulrich G. Steidl, MDPhD, Ryan G. Kruger, PhD, Richard Koche, PhD, Scott Armstrong, MD PhD

Blood (2017) 130 (Supplement 1): 242.

https://doi.org/10.1182/blood.V130.Suppl_1.242.242

Published: 2017

Journal Articles

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Blood (2015) 126 (22): 2479–2483.

https://doi.org/10.1182/blood-2015-03-635821

Published: 2015

Includes: Supplemental data

Journal Articles

Clinical Utility of Comprehensive Profiling of Genomic Alterations in Hematologic Malignancies

Blood (2014) 124 (21): 1072.

https://doi.org/10.1182/blood.V124.21.1072.1072

Published: 2014

Journal Articles

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

Blood (2014) 124 (21): 387.

https://doi.org/10.1182/blood.V124.21.387.387

Published: 2014

Journal Articles

Bmi-1 Is Dispensable for the Development of Acute Myeloid Leukemia Mediated by MLL-AF9

Tobias A Neff, MD, Florian H Heidel, MD, Scott Armstrong, MD, PhD

Blood (2010) 116 (21): 63.

https://doi.org/10.1182/blood.V116.21.63.63

Published: 2010

Journal Articles

Demonstration of a Role for Dot1l In MLL -Rearranged Leukemia Using a Conditional Loss of Function Model

Kathrin M Bernt, MD, Nan Zhu, PhD, Joerg Faber, M.D., Natalie Punt, Roy M Pollock, PhD, Victoria M Richon, PhD, Andrew L. Kung, MD, PhD, Scott Armstrong, MD, PhD

Blood (2010) 116 (21): 62.

https://doi.org/10.1182/blood.V116.21.62.62

Published: 2010

Journal Articles

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Roy M Pollock, PhD, Scott R Daigle, Edward J Olhava, PhD, Carly A Therkelsen, Christina R Majer, Jeffrey Song, Christina J Allain, Christopher J Sneeringer, L. Danielle Johnston, Margaret Porter Scott, PhD, Lei Jin, PhD, Kevin W Kuntz, PhD, Richard Chesworth, DPhil, Mikel P Moyer, PhD, Kathrin M Bernt, MD, Scott Armstrong, MD, PhD, Robert A Copeland, PhD, Victoria M Richon, PhD

Blood (2010) 116 (21): 780.

https://doi.org/10.1182/blood.V116.21.780.780

Published: 2010

Journal Articles

β-Catenin Determines Developmental Stage Specific Transformation by Hox Genes.

Yingzi Wang, PhD, Andrei V. Krivtsov, PhD, Amit U. Sinha, PhD, Trista North, PhD, Wolfram Goessling, MD, PhD, Leonard I. Zon, MD, Scott Armstrong, MD, PhD

Blood (2009) 114 (22): 385.

https://doi.org/10.1182/blood.V114.22.385.385

Published: 2009

Journal Articles

DOT1L and Histone H3 Lysine79 Methylation as a Therapeutic Target in Mixed Lineage Leukemia.

Kathrin Bernt, MD, Jorg Faber, MD, PhD, Tina N Davis, Andrew Kung, MD, PhD, Scott Armstrong, MD, PhD

Blood (2009) 114 (22): 212.

https://doi.org/10.1182/blood.V114.22.212.212

Published: 2009

Journal Articles

Cell of Origin Influences Leukemia Stem Cell Phenotype.

Andrei V. Krivtsov, PhD, Amit U. Sinha, Matthew C. Stubbs, PhD, Andrew Kung, MD, PhD, Scott Armstrong, MD, PhD

Blood (2009) 114 (22): 3459.

https://doi.org/10.1182/blood.V114.22.3459.3459

Published: 2009

Journal Articles

Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis

Christos Gekas, Katrin E. Rhodes, Laurraine M. Gereige, Hildur Helgadottir, Roberto Ferrari, Siavash K. Kurdistani, Encarnación Montecino-Rodriguez, Rhonda Bassel-Duby, Eric Olson, Andrei V. Krivtsov, Scott Armstrong, Stuart H. Orkin, Matteo Pellegrini, Hanna K. A. Mikkola

Blood (2009) 113 (15): 3461–3471.

https://doi.org/10.1182/blood-2008-07-167577

Published: 2009

Includes: Supplemental data

Journal Articles

Selective Expression of the Immunoregulatory Lectin, Galectin-1, in Precursor B Cell Acute Lymphoblastic Leukemias (ALLs) with MLL Rearrangements

Przemyslaw Juszczynski, MD, PhD, Scott J. Rodig, MD, PhD, Kunihiko Takeyama, MD, PhD, Jing Ouyang, PhD, Jorg Faber, MD, PhD, Scott Armstrong, MD, PhD, Jeffery L. Kutok, MD, PhD, Margaret A. Shipp, MD

Blood (2008) 112 (11): 2539.

https://doi.org/10.1182/blood.V112.11.2539.2539

Published: 2008

Journal Articles

Rearranged Infant Acute Lymphoblastic Leukemia.

Ronald W. Stam, PhD, Monique L. Den Boer, PhD, Pauline Schneider, Jasper de Boer, PhD, Jill Hagelstein, MSc, Stephen E. Sallan, MD, Hugh J.M. Brady, PhD, Scott Armstrong, MD, PhD, Rob Pieters, MD, PhD

Blood (2008) 112 (11): 1913.

https://doi.org/10.1182/blood.V112.11.1913.1913

Published: 2008

Journal Articles

Mir-128b Is a Potent Glucocorticoid Sensitizer in MLL-AF4 Acute Lymphocytic Leukemia Cells and Exerts Synergistic Effects with Mir- 221.

Ai Kotani, Daon Ha, Prakash Rao, James Hsieh, Diana Schotte, Monique L. den Boer, Scott Armstrong, MD, PhD, Harvey F. Lodish, PhD

Blood (2008) 112 (11): 1914.

https://doi.org/10.1182/blood.V112.11.1914.1914

Published: 2008

Journal Articles

Common Self-Renewal Pathways Contribute to the Induction of Acute Myeloid Leukemias Associated with Different Oncogenes

Brynn T Kvinlaug, BSc, MSc, Wai-In Chan, PhD, Lars Bullinger, MD, Christopher Sears, Donna Paul, Rachel Okabe, BSc, Benjamin H Lee, MD, PhD, Inusha De Silva, PhD, Scott Armstrong, MD, PhD, Hartmut Dohner, MD, D. Gary Gilliland, Brian JP Huntly, MD, PhD

Blood (2008) 112 (11): 505.

https://doi.org/10.1182/blood.V112.11.505.505

Published: 2008

Journal Articles

Genome-Wide Identification of Prednisolone-Responsive Genes in Primary Acute Lymphoblastic Leukemia Cells.

Wim J.E. Tissing, MD, Monique L. den Boer, PhD, Jules P.P. Meijerink, PhD, Renee X. Menezes, PhD, Sigrid Swagemakers, PhD, Peter J. van der Spek, PhD, Stephen E. Sallan, MD, PhD, Scott Armstrong, MD, PhD, Robrecht Pieters, MD, PhD

Blood (2005) 106 (11): 103.

https://doi.org/10.1182/blood.V106.11.103.103

Published: 2005

Journal Articles

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Blood (2005) 106 (10): 3377–3379.

https://doi.org/10.1182/blood-2005-05-1898

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting the DNA Damage Response Pathway in MLL- rearranged B-Acute Lymphoblastic Leukemias

Reciprocal Regulation of BCL6 and MLL Expression As a Vulnerability in MLL -Rearranged Acute Lymphoblastic Leukemia

LSD1 Inhibition Exerts Its Anti-Leukemic Effect By Recommissioning PU.1- and C/Ebpα-Dependent Enhancers in AML

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Clinical Utility of Comprehensive Profiling of Genomic Alterations in Hematologic Malignancies

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

Bmi-1 Is Dispensable for the Development of Acute Myeloid Leukemia Mediated by MLL-AF9

Demonstration of a Role for Dot1l In MLL -Rearranged Leukemia Using a Conditional Loss of Function Model

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

β-Catenin Determines Developmental Stage Specific Transformation by Hox Genes.

DOT1L and Histone H3 Lysine79 Methylation as a Therapeutic Target in Mixed Lineage Leukemia.

Cell of Origin Influences Leukemia Stem Cell Phenotype.

Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis

Selective Expression of the Immunoregulatory Lectin, Galectin-1, in Precursor B Cell Acute Lymphoblastic Leukemias (ALLs) with MLL Rearrangements

Rearranged Infant Acute Lymphoblastic Leukemia.

Mir-128b Is a Potent Glucocorticoid Sensitizer in MLL-AF4 Acute Lymphocytic Leukemia Cells and Exerts Synergistic Effects with Mir- 221.

Common Self-Renewal Pathways Contribute to the Induction of Acute Myeloid Leukemias Associated with Different Oncogenes

Genome-Wide Identification of Prednisolone-Responsive Genes in Primary Acute Lymphoblastic Leukemia Cells.

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only